Connect with us

BUSINESS

GT Biopharma Inc (OTCMKTS:GTBP) Promotes Dr. Raymond W Urbanski To Positon Of Chief Executive Officer

Published

on

GT Biopharma Inc (OTCMKTS:GTBP) has today announced a new change in its management. Dr. Raymond W. Urbanski is its new Chief Executive Officer following his promotion. Aside from that, he will also be serving as Chairman of the Board. He is expected to start his roles with immediate effect.

Turn of events

At the point of entry, this official was assigned the role of Chief Medical Officer. As time progressed, he was promoted to become the company’s President and CMO. That was after the business guru discovered how helpful he had been at pushing major initiatives and milestones.

In his line of work, Dr. Urbanski has been one of the big names in propelling crucial programs to highest levels of success. He has also facilitated important internal controls and processes as well. That has helped the organization enhance both its efficiency and effectiveness as well.

Dr. Urbanski worked with Pfizer Inc (NYSE:PFE) first before moving into GT Biopharma. That was over a period of about eight years within which he served in different capacities. At some point he was the company’s Vice President. The passage of time saw him rise higher to become its medical director of diversified products.

The turn of events and future expectations

The company is hoping to benefit a lot from his leadership. That is in close consideration of his extensive experience in drug development. This official also worked with Mylan NV (NASDAQ:MYL) where he was the company’s Chief Medical Officer.

It was also today that this company and (Euronext Paris: GTBP.PA) made a joint statement regarding a Material Transfer Agreement Dr. Daniel Vallera and high end Pharmaceutical provider.

GT Biopharma’s bispecific antibody drug conjugate (ADC) program has been progressing quite well under the leadership of Dr. Vallera. This official is also the big name behind the innovation of a drug candidate called OXS-1550.The target is to help persons struggling with cancer around the globe.

The official is focusing on initial work. And is optimistic it will help a great deal in making elaborate decisions regarding what tumors to target and the most appropriate doses to employ.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Health Canada Awards CDL To Medipharm Labs Corp (OTCMKTS:MEDIF) To Commence New Drug Discovery Trials: Clocks Finished Goods Supply Of 550,000 Units

Published

on

Medipharm Labs Corp (OTCMKTS:MEDIF) announced the receipt of CDL (Cannabis Drug License) from Health Canada to commence drug discovery trials.

CDL is mandatory for Medipharm to produce and supply drugs with cannabis as the key ingredient. The PPD (pharmaceutical prescription drugs) are classified with DIN (Drug Identification Number).

Positions as a vital player

CEO of Medipharm, Keith Strachan, said the demand for pharmaceutical products that comprise cannabis is growing across the world. Medipharm is already positioned as a leader in the supply of vital drugs.

Opens doors for the production of IND

Medipharm already commenced efforts to obtain GMP certification, which is vital for CDL. Keith said CDL provides an opportunity for Medipharm to engage with existing partners to enhance revenue opportunities. The company also opened the doors to work with small and larger pharma companies to manufacture innovative drugs via late-stage clinical studies.

Medipharm is geared to provide active ingredients and pharmaceutical drugs derived from cannabis to other firms that received CDL to engage in new drug discovery through clinical trials.

Reports a record supply of finished goods

In Q4 2020, Medipharm is credited with a record supply of 550,000 finished goods. Keith said the shipment volumes demonstrate its capability to satisfy Canada’s growing demand using its GMP-certified facilities. This milestone exemplifies its efforts to improve profitability in 2021 by expediting growth.

Its private-label SKUs accounted for 100,000 units out of the supplied 550,000 units in Q4 2020, increasing 75,000 SKUs compared to the previous quarter. Keith said the demand for its proprietary formulations signals growth.

Its proprietary formulations are the best sellers in several provinces. According to the Ontario store’s sales data, the cannabidiol 50 Plus formula of Medipharm is the best selling cannabidiol oil to occupy the third position in the oils category. It is on the backdrop of maintaining a strong reputation as a supplier of high purity and quality products to consumers and B2B customers through provincial distributors.

The company included 25 different types of vape SKUs in the Q4 2020 shipments. It shows the continued efforts to improve manufacturing and contract production of top cannabis brands, ensuring consistent quality.

Continue Reading

BUSINESS

An Insight From Akerna Corp (NASDAQ:KERN) Shows That Female Purchasers Account for 3% YoY Cannabis Sales Growth During The Valentine’s Day Weekend in 2021

Published

on

The business intelligence gained from Akerna Corp (NASDAQ:KERN) indicates that female purchasers account for a 3% YoY growth in cannabis sales during Valentine’s Day this year.

Females prefer cannabis flower

The females contributed to over 38% of the cannabis sales in 2021 compared to 25% during the previous year. Cannabis flower is the women’s favorite during the Valentine’s Day weekend in 2021. It accounted for 48% of the total cannabis sales, an increase of 3% compared to other categories like infused edibles, concentrates, pens, and cartridges.

Women’s spending on cannabis flower increases

Women’s spending on cannabis flower in 2021 surged to 45% compared to an increase of 35% in 2020.

BI Architect of Akerna, James Ahrendt, said females are the contributing factor in the sales of cannabis. It is evident from the household purchases. As a result, the companies target hemp and CBD brands and cannabis products to satisfy the needs of female customers.

Valentine’s Day sales of cannabis

The total cannabis sales during the Valentine’s Day weekend in 2021 are $170 million.

The daily lives of people in North America are altered since the onset of coronavirus. As a result, the spending on cannabis increased by 25 to 30%.

The sales of recreational cannabis rose to $60 in 2020 from $48 in 2019. Medical cannabis sales per visit surged to $123 in 2020 from $100 in 2019. James said cannabis enjoyed a dream run last year.

People are buying more cannabis products in each visit. Businesses engaging in cannabis can note this change and make plans to boost their sales. They should focus on flower compared to other categories and educate the customers about the benefits.

Prospects of cannabis in 2021

After great political strides in 2020, the cannabis industry expects to gain more as it moves towards legalization at the state level. It expects to attract more funding and mergers and acquisitions.

Consolidation is expected in the cannabis industry, with political preferences moving towards legalization in the US. According to cannabis law expert Eric Berlin, mergers and acquisitions is more strategic, mainly for distressed assets. Companies that have good assets but have not achieved success are good acquisition candidates.

Continue Reading

BUSINESS

Agraflora Organics International Inc (OTCMKTS:AGFAF) Will Report First Revenues From Gelato, Kosher Kush, And Mimosa 37 In Summer

Published

on

Agraflora Organics International Inc (OTCMKTS:AGFAF) expects to realize its first revenues from three proprietary strains Gelato, Kosher Kush, and Mimosa 37 Summer. The attributes of these cannabis strains include high THC and affordability.

Satisfies demand for dried flower

Agraflora cultivated these proprietary strains in its Propagation Services Canada Inc. (PSCI), the cannabis manufacturing facility based in Delta, BC. It helps the company to satisfy the growing demand for dried flowers in Canada. PSCI is establishing a leadership role in offering economical and high THC cannabis strains.

General Manager, Ruben Houweling said the company incorporated changes to its infrastructure recently to improve drying capacity significantly. It helps the company to enhance summer revenues this year.

A global partner calibrated and incorporated changes to the prevailing drying rooms of PSCI. This helps PSCI to almost double its drying capacity with lower capital needs. The plant will also fine-tune its settings to manufacture rooted and healthy cuttings quickly.

Optimization of propagation strategies helps PSCI to produce customized nutrient formulations at each stage of the plant growth. It leads to higher yields per sq. meter with minimal spending on labor.

Settles the services by issuing common shares

The board of directors of Agraflora agreed to settle the services through the issue of its common shares. Agraflora issued 1.42 million common shares to settle the debt of $71,000.92. All the issued shares are subjected to a holding period of four months and one day from the date of issue.

Completes R&D trials

Agraflora completed R&D trials first-phase at its Winnipeg, Manitoba-based licensed 51,000 sq. Ft. edibles production facility and gears for an entry into the edibles market in Q1 2021. Agraflora can now achieve desired formulations and produce desired varieties using its efficient processes.

Manager (operations) of EIC, James Fletcher said the company is expediting supply contracts with its licensed manufacturers to produce gummies with desired flavors. The company utilizes the confectionary experience of over 97 years to produce gummies to satisfy the demand of several LP clients.

According to the board of directors, the company introduces tasty and high-quality gummies at the right time to satisfy the demand. The gummies category commands the highest share in the edibles sector.

Continue Reading

Trending Stories